This article and associated images are based on a poster originally authored by Kieran Casey, Yuzhou Xu, Jichuan Zhang, Shuyue Wang, Yanfei Hu, Ye Tian, Min Lyu, Ziyu Chen, Ya Xu, Qikuan Chen and ...
Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...
The "Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's offering. First conceptualized in the early 2000s, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results